# NAD+ side effects: what trials and regulators have recorded

Updated 2026-10-17.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme the body makes. The side effects recorded depend on the form studied. In a crossover trial of 30 healthy middle-aged and older adults, 7 people reported 14 adverse events on nicotinamide riboside or placebo. All were mild. The trial was small and the events were self-reported (Martens et al., 2018). A 2026 meta-analysis covered 10 adult randomised trials of nicotinamide mononucleotide. It found no rise in adverse events against control groups. The trials lasted 14 days to 24 weeks, so they cannot show long-term safety (Yang et al., 2026). In its notice of 30 October 2024, the US FDA said it had received adverse event reports after use of NAD+ drugs. These were severe chills, shaking, vomiting and fatigue. The notice gives no count of reports and no denominator (FDA, 30 October 2024).

| | |
| --- | --- |
| Compound | NAD+ (nicotinamide adenine dinucleotide), a coenzyme. |
| Forms covered | NMN; nicotinamide riboside (NR); NAD+ drug products; compounded NAD+ products. |
| NMN, pooled safety analysis | 15 adult randomised trials in the review, 10 in the safety analyses with 383 participants (Yang et al., 2026). |
| Systematic review of human studies | 33 human intervention studies, 28 randomised (Gallagher and Emmanuel, Ageing Research Reviews, 2026). |
| Largest NR safety trial opened | 140 overweight adults, 8 weeks, no serious events; short trial, not evidence excluding rare or long-term harm (Conze et al., 2019). |
| Human NAD+ pilot | 11 men, no adverse events observed; too small to estimate a rate (Grant et al., 2019). |
| FDA adverse event reports | Severe chills, shaking, vomiting and fatigue following use of NAD+ drugs, some requiring medical treatment ([FDA notice, 30 October 2024](https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding)). |
| Sources read | 14 October 2026 |

Your body builds and spends NAD+ around the clock, in nearly every cell, without any help from you. A molecule that busy is easy to think of as harmless. That is exactly why the question of side effects needs a careful answer. In the records read for this page, the harms reported are tied to particular products or lots. One example is the lot with high endotoxin described below. None of the records measures harm from the NAD+ that cells make themselves.

This page is part of [the NAD+ hub](/learn/nad-plus). It sets out the adverse events that named trials, regulators and case records have recorded, form by form. It says plainly what has not been measured. It reports published findings only and gives no advice. Research material is not a medicine.

## What side effects are reported with NAD+?

The side effects recorded for NAD+ depend on the form studied. A 2026 systematic review of 33 human studies found nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) generally well tolerated over weeks to months. The review calls for trials with longer follow-up. So it cannot show long-term safety (Gallagher and Emmanuel, 2026). A 2026 meta-analysis covered 10 adult randomised NMN trials. It found no rise in overall or serious adverse events against control groups. The trials ran only 14 days to 24 weeks (Yang et al., 2026). In a crossover trial of 30 healthy middle-aged and older adults, NR events were mostly mild. Examples were nausea, flushing and leg cramps. Several happened in placebo weeks, which limits what the trial can say about causes (Martens et al., 2018). The US Food and Drug Administration (FDA) separately said it had received adverse event reports after use of NAD+ drugs. These were severe chills, shaking, vomiting and fatigue. The reports describe events without a rate ([FDA notice, 30 October 2024](https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding)).

The same word, NAD+, covers very different products, so one list of side effects would mislead. The table after these sections sets each form beside its record. The [NAD+ research guide](/research/nad-plus) covers what the molecule is. [NAD+ is not a peptide](/learn/peptide-quality-verification/is-nad-plus-a-peptide) settles the naming question.

Counts depend on who is counting. In a crossover trial of 30 healthy middle-aged and older adults, 7 people reported 14 events in all. Every one was mild. Nine happened during the placebo weeks and five during the NR weeks. The trial cannot say which events NR caused. The events were self-reported in a small group (Martens et al., 2018). In an 8-week trial of 140 overweight adults, the supplier paid for the work. 61 people reported 95 events across a placebo group and three NR groups. There were no serious events and no flushing. The type, rate and severity of events were similar across groups. It was a short trial that cannot exclude rare or long-term harm (Conze et al., 2019).

## What is the NAD+ controversy, in three records?

The NAD+ debate mixes study findings, ingredient rules and production warnings. These records answer different questions about different products. A study can measure changes in blood without showing better health. A rule names the substance and product it covers. A warning about how a product was made cannot settle whether another product works.

Study findings: the Gallagher and Emmanuel review from 2026 found clear changes in blood markers with NR and NMN. These are substances the body can turn into NAD+. Yet health results varied, and many showed no clear change. A blood marker is a test reading. It is not a measure of feeling well.

Ingredient rules: the TGA notice names NAD+, NADH and NMN separately. Its NMN rules concern an ingredient used in listed medicines. The [Australian status page](/learn/nad-plus/is-nad-plus-legal-in-australia) explains the terms. The TGA record was checked on 17 October 2026. One ingredient rule cannot stand for every product called NAD.

Production warnings: the FDA reminder concerns ingredients used to make sterile drugs. Sterile means free from living germs. Its warning letter dated 20 January 2026 records problems at a production site. Neither document is a trial of daily wellbeing. Read these records as separate kinds of evidence.

![Three separate cards labelled Study finding, Ingredient rule and Production warning, showing different kinds of evidence.](/assets/content/hub-coenzyme-three-records.png)

Study results, ingredient rules and production warnings answer different questions. Sources: Gallagher and Emmanuel, Ageing Research Reviews, 2026; TGA NAD medicines notice, checked 17 October 2026; FDA sterile-compounding reminder.

## What have the safety studies not shown?

The safety studies of NAD+ precursors are short, small and mostly in adults without serious illness. The 2026 meta-analysis of NMN trials covers 10 adult randomised trials with 383 participants in its safety analyses. They lasted 14 days to 24 weeks. It cannot speak to long-term safety (Yang et al., 2026). A systematic review of 33 human studies from January 2010 to October 2025 found no eligible outcomes trial of intravenous or intramuscular NAD+ for anti-aging or wellness (Gallagher and Emmanuel, 2026). A 2020 systematic review of 147 articles, 113 preclinical and 34 clinical, said long-term human trials of NAD+ precursors are still new (Braidy and Liu, 2020). No recorded event in a trial is not proof that none occurs.

Trial design adds its own limits. Martens and colleagues gathered events by self-report at check-in visits. They wrote that a group of 30 is too small to show the wider safety profile of NR (2018). The 140-adult NR trial was funded by the supplier of the compound it tested. Two authors work for that supplier (Conze et al., 2019).

No source opened for this page reports how often any side effect happens in people who use NAD+ products outside trials. The FDA notice describes reports it received after use of NAD+ drugs. It gives no denominator.

## What do human studies conclude about the safety of NAD+ supplements?

A systematic review of 33 human studies found NR and NMN generally well tolerated over weeks to months. It judged the clinical effect for anti-aging or wellness inconclusive. The review calls for trials with longer follow-up. It cannot show long-term safety (Gallagher and Emmanuel, 2026). This review is not a safety finding for every person.

Trials enrolled specific groups. A 4-week NMN trial enrolled 31 healthy adults aged 20 to 65 (Fukamizu et al., 2022). A 12-week NR trial enrolled 40 sedentary obese men aged 40 to 70 (Dollerup et al., 2018). A 30-day NR trial enrolled 30 people newly diagnosed with Parkinson's disease (Brakedal et al., 2022). The trials described on this page enrolled adults.

The Therapeutic Goods Administration (TGA) sets requirements for listed medicines that contain NMN. They specify an adult use. They give no use for pregnant or breastfeeding women ([TGA safety alert, last updated 3 February 2026](https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/nad-nad-nadh-or-nmn-medicines-sold-australia)). That is a regulatory requirement, not a safety finding. [Is NAD+ legal in Australia?](/learn/nad-plus/is-nad-plus-legal-in-australia) sets out that record.

## What side effects did trials of nicotinamide mononucleotide (NMN) record?

In a 4-week trial of 31 healthy adults aged 20 to 65, five events were recorded. They were loose stool twice, a common cold, high blood pressure and acne. No severe adverse events were seen. The investigators judged none of the five related to NMN. A trial this small cannot confirm that for rarer events (Fukamizu et al., 2022). A 12-week trial of 30 healthy adults (15 on NMN, 15 on placebo) found no abnormal results in physical and lab tests. It found no obvious adverse effects. Again, the group was small and healthy (Okabe et al., 2022).

In 80 healthy middle-aged adults followed for 60 days, there were three NMN groups and a placebo group. No safety issues appeared in adverse events, lab tests or clinical measures. The result is limited to that group and that length (Yi et al., 2023). In 30 overweight or obese adults aged 45 or older followed for 28 days, adverse events were similar between the NMN and placebo groups. It was a small, short trial (Pencina et al., 2023).

Each of these trials is small and short. The meta-analysis in the next sections covers 10 adult randomised trials with 383 participants in its safety analyses (Yang et al., 2026).

## Is NMN toxic to the liver?

A 2026 meta-analysis of adult randomised NMN trials found that NMN did not significantly raise ALT or AST. These are the two blood enzymes used to check for liver stress. The analysis covered 10 comparisons with 330 participants over 14 days to 24 weeks. It cannot show long-term liver safety (Yang et al., 2026). In a 4-week trial of 31 healthy adults, biochemical measures did not change beyond normal variation. The group was small and healthy, so it cannot exclude rare or long-term harm (Fukamizu et al., 2022). Sprague-Dawley rats were given NMN for 90 days. Organ toxicity checks and tissue examinations showed no toxic effects. This is a rat result and does not show human safety (Cros et al., 2021).

A second rat study gave NMN to Sprague-Dawley rats for 91 days. It found no test-item-related adverse findings at its lowest amount. Body weight, weight gain and food intake fell in the highest group. The nicotinamide riboside reference showed the same pattern. The result is from rats, not from people (Turner et al., 2021).

The related compound nicotinamide behaves differently. Memorial Sloan Kettering's [About Herbs page](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/nicotinamide) lists liver toxicity among the effects linked to high amounts of nicotinamide. It says niacin and nicotinamide are not interchangeable (page last updated 21 February 2023). NMN is a different molecule. The trials above are the evidence for NMN itself.

## What side effects did trials of nicotinamide riboside record?

In an 8-week randomised trial of 140 overweight adults, 61 people reported 95 adverse events. None was serious. There was no flushing. The type, rate and severity of events were similar across the placebo and three NR groups. The trial was paid for by the supplier and was short (Conze et al., 2019). In a 12-week randomised trial of 40 obese men, no serious adverse events were attributed to NR. Safety blood tests were normal. The group was one set of men (Dollerup et al., 2018).

In the NR crossover trial of 30 healthy middle-aged and older adults, the events listed under NR were single reports. They were nausea, skin rash, flushing, leg cramps and more bruising. The group was small and the periods were two 6-week blocks (Martens et al., 2018). A 30-day phase 1 trial enrolled 30 people newly diagnosed with Parkinson's disease. NR was well tolerated. It was a small, short trial in one condition (Brakedal et al., 2022). A 4-week phase 1 trial enrolled 20 people with Parkinson's disease (10 on high-amount NR, 10 on placebo). No moderate or severe adverse events were recorded. Mild events did not differ significantly between groups. Serum homocysteine rose slightly early on in NR recipients. Again, the group was small (Berven et al., 2023).

Flushing was tracked in two NR trials. In an 8-week trial of 140 overweight adults, the supplier paid for the work. Conze and colleagues reported no flushing with NR. It was a short trial that cannot exclude rare events (2019). In a crossover trial of 30 healthy middle-aged and older adults, Martens and colleagues recorded one flushing event in the NR weeks against two in the placebo weeks. It was a small trial with self-reported events (2018).

## What adverse events have been recorded after NAD+ is given by IV?

In a pilot of 11 men, eight were given NAD+ and three were given saline. No adverse events were observed. A group this small cannot show how often events occur (Grant et al., 2019). The FDA says it received adverse event reports after use of NAD+ drugs. They were severe chills, shaking, vomiting and fatigue, and some needed medical treatment. The reports carry no rate ([FDA notice, 30 October 2024](https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding)).

In a [warning letter dated 20 January 2026](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026), the FDA describes a complaint about three patients. They developed low blood pressure, uncontrollable shaking, shivers and body aches shortly after or during a compounded NAD+ product. They were directed to an emergency room. This is an inspection record about one facility. It is not a controlled study (FDA warning letter 718739, 20 January 2026). The [FDA notice](https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding) calls the reactions it received consistent with excessive levels of endotoxins. Endotoxins are fragments of bacterial cell walls (FDA notice, content current as of 30 October 2024).

The two records describe different things. One is a small pilot with a saline comparison group. The other is reports the FDA gathered after clinical use of compounded products. A systematic review also found one non-randomised NMN study. It mainly added short-term safety and biomarker information (Gallagher and Emmanuel, 2026). No source opened here reports how common any side effect is for compounded NAD+ products.

## What has the FDA said about compounded NAD+ products?

The FDA has warned compounders about NAD+ in two documents read for this page. A [notice with content current as of 30 October 2024](https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding) says the agency knows that compounders use food-grade NAD+ sold by repackagers. It says ingredients identified as food grade are not suitable for compounding sterile drugs without proper processing. The reason is the high risk of contamination with microbes and endotoxins. A [warning letter dated 20 January 2026](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026) went to one US outsourcing facility. It states that NAD+ does not appear on the 503B bulks list. It also states that an unopened vial from one lot of its NAD+ product contained excessive bacterial endotoxins. The letter concerns that facility and that lot (FDA warning letter 718739).

The letter records the finding in detail. An unopened vial from the lot tested at 3,360 endotoxin units per millilitre. The firm began a voluntary recall of its sterile drug products on 30 July 2025 (FDA warning letter 718739, 20 January 2026). Compounders are pharmacies and outsourcing facilities that prepare custom drugs. The 503B bulks list names the bulk drug substances with a clinical need that an outsourcing facility may use in compounding (FDA warning letter 718739).

The letter concerns one outsourcing facility and its lots. It is not a statement about every NAD+ product. [NAD+ legal status in Australia](/learn/nad-plus/is-nad-plus-legal-in-australia) covers the Australian side.

## How long does NAD+ stay in the blood after an IV infusion?

The only human data on plasma NAD+ after NAD+ was given come from a 2019 pilot. The paper reports no half-life. Eight men were given NAD+. Their plasma NAD+ and its breakdown products did not change until after the 2-hour mark. The authors conclude that NAD+ was quickly and fully removed from plasma for at least the first 2 hours under the conditions tested. The paper gives no clearance time (Grant et al., 2019). Six-hour urine samples from the same eight men showed more methylnicotinamide and NAD+. This small study of breakdown products did not set a whole-body clearance time.

The limits are large. The test group was eight men aged 30 to 55 with a body mass index under 30. They were studied under one set of conditions, with three saline controls (Grant et al., 2019). The paper shows what appeared in plasma and urine in that one pilot. It does not give a clearance time. It does not cover other forms of NAD+.

## What risks have researchers raised about raising NAD+ levels?

Researchers have listed possible risks of raising NAD+ levels. The human trials above lasted only weeks to months. A systematic review of 147 articles, 113 preclinical and 34 clinical, described a limited acute toxicity profile for NAD+ precursors. It named possible risks. They were build-up of toxic by-products, tumour growth and promotion of cell aging. It added that evidence is limited (Braidy and Liu, 2020). The review presents these as possible risks. They are not observed outcomes in the human trials above.

A separate line of work concerns niacin, not NAD+ itself. Two groups of stable heart patients (2,331 and 832 people) were followed for 3 years. Blood levels of 2PY and 4PY, the end products of excess niacin, went with a higher risk of major adverse heart and blood vessel events. 4PY also switched on a vascular adhesion protein in mice. That is a mouse result and does not show a human result. The study measured niacin by-products, not NMN or NR. It does not show that an NAD+ precursor raises that risk (Ferrell et al., 2024).

The [TGA alert](https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/nad-nad-nadh-or-nmn-medicines-sold-australia) states that some products make claims about NAD, NAD+, NADH or NMN without an AUST number on the label. They may be unapproved goods or illegally supplied. They could pose a risk to health (TGA safety alert, last updated 3 February 2026).

## What do official medical sources say about NAD+ side effects?

The official sources opened for this page cover different products. Their records cannot be treated as one safety finding for NAD+. The TGA says some products make claims about NAD, NAD+, NADH or NMN without an AUST number on the label. They may be unapproved goods or illegally supplied. They could pose a risk to health ([TGA safety alert, last updated 3 February 2026](https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/nad-nad-nadh-or-nmn-medicines-sold-australia)). The FDA notice covers NAD+ ingredients used by compounders ([FDA notice, content current as of 30 October 2024](https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding)). Memorial Sloan Kettering's [About Herbs page](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/nicotinamide) lists nausea, vomiting, headache, fatigue, dizziness and liver toxicity as linked to high amounts of nicotinamide, a related vitamin. It describes nicotinamide, not NAD+ (page last updated 21 February 2023).

A search of the Memorial Sloan Kettering site on 14 October 2026 returned no separate entry for nicotinamide riboside. The trial reports and reviews cited on this page are indexed in PubMed, the US National Library of Medicine database. They are the main published evidence for NR and NMN found in the sources searched.

An ARTG number shows that a medicine is on the [Australian Register of Therapeutic Goods](https://www.tga.gov.au/resources/artg). It appears on the label as AUST L, AUST L(A) or AUST R (TGA safety alert, last updated 3 February 2026).

## Is research-use NAD+ the same material these studies measured?

No. Every safety figure on this page was measured on a trial product or recorded in clinical use. None describes research-use reference material. Research material is not a medicine and is not a substitute for one. It is not for human or animal use. The trial products were identified supplies given under study protocols. One NR trial was funded by the supplier of the compound it tested (Conze et al., 2019). The trial results describe what happened inside those trials. They say nothing about any material outside them.

The site catalogue lists [NAD+ reference material](/shop/nad-plus) as a laboratory item. What a batch document can and cannot show is a separate subject from what a trial measured. The two should not be merged.

## Comparison

Adverse events by form, as recorded in the named source. Trial sizes are the numbers enrolled or analysed in the cited paper. This is not a safety guarantee and not advice.

| Form | Model and size | Adverse events recorded | Source |
| --- | --- | --- | --- |
| NR, 8 weeks | Randomised trial, 140 overweight adults | In 140 overweight adults over 8 weeks, 95 events in 61 participants, none serious and no flushing, similar across the placebo and three NR groups, in a short supplier-funded trial (Conze et al., 2019). | Conze et al., Scientific Reports, 2019 |
| NR, 2 x 6 weeks | Randomised crossover trial, 30 healthy middle-aged and older adults. | In 30 healthy middle-aged and older adults randomised, 7 participants reported 14 mild events and none was serious (9 in placebo weeks, 5 in NR weeks), in a small crossover trial with self-reported events (Martens et al., 2018). | Martens et al., 2018 |
| NR, 12 weeks | Randomised trial, 40 obese men | In 40 obese men over 12 weeks, no serious adverse events were attributed to NR and safety blood tests were normal, in one selected group of men over a limited period (Dollerup et al., 2018). | Dollerup et al., 2018 |
| NMN, 4 weeks | Randomised trial, 31 healthy adults | In 31 healthy adults over 4 weeks, 5 events were recorded, none judged related to NMN and none severe, in a small trial that cannot exclude rare events (Fukamizu et al., 2022). | Fukamizu et al., 2022 |
| NMN, pooled | Meta-analysis, 10 adult randomised trials in safety analyses (383 participants). | In 10 adult randomised trials with 383 participants, NMN did not increase overall, serious or system-specific events, and 10 comparisons with 330 participants showed no significant ALT or AST rise. The trials ran 14 days to 24 weeks and cannot speak to long-term safety (Yang et al., 2026). | Yang et al., Nutrients, 2026 |
| NAD+, pilot | Pilot, 11 men (8 given NAD+, 3 saline) | In 11 men, 8 given NAD+ and 3 given saline, no adverse events were observed, too small to estimate a rate (Grant et al., 2019). | Grant et al., 2019 |
| Compounded NAD+, one lot with high endotoxin | Complaint investigation at a US outsourcing facility, 3 patients. | In a complaint about 3 patients at one US outsourcing facility, low blood pressure, uncontrollable shaking, shivers and body aches followed a compounded NAD+ product. An unopened vial from the lot tested high for endotoxin. One facility, one lot, an inspection record and not a controlled study (FDA warning letter 718739, 20 January 2026). | [FDA warning letter 718739](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026), 20 January 2026. |

## Frequently asked questions

### What have studies of NAD+ found, and what side effects did they record?

A 2026 systematic review of 33 human studies found that NR and NMN consistently raised NAD-related substances in blood or cells. They were generally well tolerated over weeks to months. The review calls for trials with longer follow-up (Gallagher and Emmanuel, 2026). In the same 33 studies, the products, groups and lengths differed. Effects on body function and metabolism were mixed and often null (Gallagher and Emmanuel, 2026). [What human studies measured](/learn/nad-plus/do-nad-plus-supplements-work) sets out the findings. This page sets out the adverse events.

### Is NAD+ safe for anyone?

A trial result describes the group studied, not everyone. The trials in this page enrolled adults in named groups, such as healthy adults aged 20 to 65 (Fukamizu et al., 2022). A 2026 systematic review of 33 human studies called NR and NMN generally well tolerated over weeks to months. It calls for trials with longer follow-up and cannot show long-term safety (Gallagher and Emmanuel, 2026).

### What do studies say about the safety of nicotinamide mononucleotide?

A 2026 meta-analysis covered 10 adult randomised NMN trials. It found no rise in overall or serious adverse events against controls. The trials ran for 14 days to 24 weeks, so they cannot show long-term safety (Yang et al., 2026). A 4-week trial of 31 healthy adults saw no severe adverse events. It was a small trial that cannot exclude rare or long-term harm (Fukamizu et al., 2022).

### What dangers have researchers raised about NMN?

A 2020 systematic review of 147 articles on NAD+ precursors, 113 preclinical and 34 clinical, lists possible risks. They include build-up of toxic by-products and tumour growth. The review notes that evidence is limited (Braidy and Liu, 2020). Products outside trials may differ from the trial products. The [TGA alert](https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/nad-nad-nadh-or-nmn-medicines-sold-australia) states that unapproved goods may pose a risk to health (TGA safety alert, last updated 3 February 2026).

### Is NAD a side effect?

No. NAD+ is a coenzyme for redox reactions that is central to energy metabolism (Covarrubias et al., 2021). In the 33 studies of a 2026 systematic review, a rise in NAD-related substances was reported as a measured result. It was not reported as a side effect. A change in these substances does not show clinical benefit or general safety (Gallagher and Emmanuel, 2026).

### What are the common side effects of NAD+ given by IV or by shot?

No trial opened for this page measured how common they are. The only pilot study recorded none in 11 men, a group too small to estimate a rate (Grant et al., 2019). The FDA says it received adverse event reports after use of NAD+ drugs. They were severe chills, shaking, vomiting and fatigue. There is no count of reports ([FDA notice, 30 October 2024](https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding)).

### What do PubMed trials, the FDA and Memorial Sloan Kettering say about NAD+ side effects?

A 2026 systematic review of 33 human studies, indexed in PubMed, found NR and NMN generally well tolerated over weeks to months. The review calls for trials with longer follow-up and cannot show long-term safety (Gallagher and Emmanuel, 2026). The [FDA notice](https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding) reports severe reactions after use of NAD+ drugs, with no count of reports. Memorial Sloan Kettering's [page on the related vitamin nicotinamide](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/nicotinamide) lists nausea, headache, fatigue and liver toxicity as linked to high amounts. It had no separate NR entry in the search of 14 October 2026.

## Citations

- Martens CR et al.. Nature Communications. 2018;9:1286. DOI: 10.1038/s41467-018-03421-7
- Conze D et al.. Scientific Reports. 2019;9:9772. DOI: 10.1038/s41598-019-46120-z
- Dollerup OL et al.. American Journal of Clinical Nutrition. 2018;108(2):343-353. DOI: 10.1093/ajcn/nqy132
- Fukamizu Y et al.. Scientific Reports. 2022;12:14442. DOI: 10.1038/s41598-022-18272-y
- Okabe K et al.. Frontiers in Nutrition. 2022;9:868640. DOI: 10.3389/fnut.2022.868640
- Yi L et al.. GeroScience. 2023;45(1):29-43. DOI: 10.1007/s11357-022-00705-1
- Pencina KM et al.. Journal of Clinical Endocrinology and Metabolism. 2023;108(8):1968-1980. DOI: 10.1210/clinem/dgad027
- Brakedal B et al.. Cell Metabolism. 2022;34(3):396-407. DOI: 10.1016/j.cmet.2022.02.001
- Berven H et al.. Nature Communications. 2023;14:7793. DOI: 10.1038/s41467-023-43514-6
- Yang W et al.. Nutrients. 2026;18(14). DOI: 10.3390/nu18142251
- Gallagher C, Emmanuel OO.. Ageing Research Reviews. 2026;116:103057. DOI: 10.1016/j.arr.2026.103057
- Freeberg KA et al.. The Journals of Gerontology: Series A. 2023;78(12):2435-2448. DOI: 10.1093/gerona/glad106
- Grant R et al.. Frontiers in Aging Neuroscience. 2019;11:257. DOI: 10.3389/fnagi.2019.00257
- Braidy N, Liu Y.. Experimental Gerontology. 2020;132:110831. DOI: 10.1016/j.exger.2020.110831
- Ferrell M et al.. Nature Medicine. 2024;30(2):424-434. DOI: 10.1038/s41591-023-02793-8
- Cros C et al.. Food and Chemical Toxicology. 2021;150:112060. DOI: 10.1016/j.fct.2021.112060
- Turner J et al.. Frontiers in Pharmacology. 2021;12:749727. DOI: 10.3389/fphar.2021.749727
- Covarrubias AJ et al.. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141. DOI: 10.1038/s41580-020-00313-x

[NAD+ reference material](/shop/nad-plus)

Research use only: not for human or animal use.

[Read the NAD+ research guide](/research/nad-plus)

---

Canonical page: https://www.formlaboratories.com/learn/nad-plus/nad-plus-side-effects

Form Laboratories - Perth-based research-use-only peptide supplier, shipping Australia-wide.

- Site guide for agents: https://www.formlaboratories.com/llms.txt
- Sitemap: https://www.formlaboratories.com/sitemap.xml
- Full catalogue: https://www.formlaboratories.com/shop
- Contact: hello@formlaboratories.com

All materials are supplied for laboratory research use only - not for human or veterinary use, and nothing on this site is medical advice.